Cat. #151245
Anti-Cdk2 [AN21.2]
Cat. #: 151245
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Cyclin-dependent kinase 2 (cdk2)
Class: Monoclonal
Application: ELISA ; WB
Reactivity: Human ; Mouse ; Xenopus laevis
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Julian Gannon
Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Cdk2 [AN21.2]
- Alternate name: Cyclin-Dependent Kinase 2; Cell Division Protein Kinase 2; P33 Protein Kinase; CDKN2; CDC2-Related Protein Kinase; P33(CDK2)
- Research fields: Cancer;Cell biology;Genetics
- Clone: AN21.2
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human ; Mouse ; Xenopus laevis
- Host: Mouse
- Application: ELISA ; WB
- Description: AN21.2 is useful as a general CDK antibody since it reacts with both Cdk1 and Cdk2.
- Immunogen: Human recombinant Cdk2
- Isotype: IgG2a
- Myeloma used: Sp2/0-Ag14
Target Details
- Target: Cyclin-dependent kinase 2 (cdk2)
- Target background: Cdk2 is a cell cycle protein closely related to Cdk1 (Cdc2) and a useful marker of proliferation. Cdk2 binds cyclins A and E and controls progression into S-phase.
Applications
- Application: ELISA ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Lee et al. 2012. Evid Based Complement Alternat Med. 2012:702857. PMID: 22701509.
- Inhibition of Cell Growth and Induction of Apoptosis by Antrodia camphorata in HER-2/neu-Overexpressing Breast Cancer Cells through the Induction of ROS, Depletion of HER-2/neu, and Disruption of the PI3K/Akt Signaling Pathway.
- Huang et al. 2008. Cell Cycle. 7(18):2846-55. PMID: 18769144.
- ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage.
